XASX
RCE
Market cap77mUSD
Jul 10, Last price
0.39AUD
1D
2.67%
1Q
-19.79%
Jan 2017
133.33%
IPO
26.23%
Name
Recce Pharmaceuticals Ltd
Chart & Performance
P/E
—
P/S
15.35
EPS
—
Div Yield, %
—
Shrs. gr., 5y
13.03%
Rev. gr., 5y
46.26%
Revenues
8m
+49.33%
Net income
-21m
L+21.33%
CFO
-20m
L+57.14%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Recce Pharmaceuticals Ltd is a biotechnology firm dedicated to the discovery, development, and commercialization of cutting-edge synthetic anti-infective treatments. The company's operations span major markets, including Australia, the United States, and the United Kingdom. Its primary drug candidate, RECCE 327, is engineered to combat severe blood infections and sepsis caused by E. coli and S. aureus bacteria, critically, even their antibiotic-resistant 'superbug' forms. In addition to RECCE 327, the company's pipeline includes RECCE 529, another synthetic anti-infective being developed for viral infections, and RECCE 435, a synthetic polymer anti-infective. Founded in 2007, the company originally operated as Recce Limited before officially rebranding to Recce Pharmaceuticals Ltd in November 2017. It maintains its headquarters in Sydney, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||